Compare HIMS & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIMS | AXSM |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 7.5B |
| IPO Year | 2019 | 2015 |
| Metric | HIMS | AXSM |
|---|---|---|
| Price | $18.55 | $136.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 22 |
| Target Price | $28.31 | ★ $265.86 |
| AVG Volume (30 Days) | ★ 12.7M | 1.0M |
| Earning Date | 11-09-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,347,637,000.00 | N/A |
| Revenue This Year | $33.80 | $49.13 |
| Revenue Next Year | $23.08 | $52.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 59.00 | N/A |
| 52 Week Low | $13.74 | $123.00 |
| 52 Week High | $40.99 | $260.19 |
| Indicator | HIMS | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 31.83 | 38.01 |
| Support Level | $13.74 | $123.00 |
| Resistance Level | $30.72 | $225.16 |
| Average True Range (ATR) | 2.12 | 7.91 |
| MACD | -0.78 | 2.11 |
| Stochastic Oscillator | 1.66 | 52.94 |
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.